Phase I dose escalation trial using stereotactic body radiation therapy (SBRT) for partial breast irradiation (PBI).

医学 肿块切除术 美容 队列 乳腺癌 耐受性 放射治疗 核医学 外科 乳房切除术 放射科 癌症 内科学 不利影响
作者
Asal Rahimi,Ann Spangler,Dan Garwood,A. Marilyn Leitch,Roshni Rao,Stephen J. Seiler,Rachel Wooldridge,Aeisha Rivers,Stella Stevenson,Sally Goudreau,Barbara Haley,Ying Dong,David Euhus,Kevin Albuquerque,M.R. Folkert,J.H. Heinzerling,Chuxiong Ding,Chul Ahn,Hak Choy,Robert Timmerman
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:33 (15_suppl): 1057-1057 被引量:2
标识
DOI:10.1200/jco.2015.33.15_suppl.1057
摘要

1057 Background: To evaluate tolerability of escalating doses of 5 fraction SBRT PBI in treating early stage breast cancer after partial mastectomy on a phase I dose escalation trial. The primary objective was to escalate the PBI dose utilizing a robotic stereotactic radiation system treating the lumpectomy cavity without exceeding the maximum tolerated dose (MTD). Methods: Eligible patients included DCIS or invasive ductal histologies, AJCC stage 0-II with tumor size < 3cm, and margins ≥ 2mm. Prior to simulation 3-4 four gold fiducials were placed around the lumpectomy cavity for real-time respiratory tracking. Dose limiting toxicity (DLT) equaled grade ≥ 3 toxicity by CTCAE deemed definitely related to treatment for: skin, bone (fracture), pulmonary, neurological (intercostal or brachial plexus nerves) or any grade 4/ 5 toxicity definitely attributed to therapy. Both patients and physicians completed baseline and subsequent cosmesis questionnaires using a four point scale – excellent, good, fair, poor. Starting dose was 30 Gy in 5 fractions. Dose was escalated by 2.5 Gy total, provided 4 or fewer of 15 patients experienced a DLT within 90 days of treatment within each dose group. If more patients had DLT in a given dose cohort, the MTD would be exceeded. Results: 68 patients (15 per dose cohort (cohort 5 -8 patients)) enrolled with median age 62 years. Median follow-up for cohorts 1,2,3,4, and 5 were - 36.3, 26.4, 16, 8.8, and 2.3 months. The first 3 dose cohorts completed 90 day follow-up without DLTs. There was 1 focal grade 3 dermatitis DLT at 37.5 Gy. DLT follow-up is still ongoing in cohort 5. There were 72 grade 1 toxicity events, 2 grade 2 toxicities (rib fracture and breast pain), and 2 grade 3 radiation dermatitis toxicities. Physicians scored cosmesis as excellent or good in 94.9%, 100%, 97.7%, and 100% respectively (p = 0.28), at baseline, 6, 12, and 24 months post SBRT, while patients scored the same periods 82.7%, 96.2%, 95.4%, and 92.8% (p = 0.04). Conclusions: Dose is escalated to 37.5 Gy in 5 fractions without MTD thus far. Soon we are completing dose escalation for 40Gy in 5 fractions PBI, hoping to increase the likelihood of long term tumor control while evaluating toxicity and cosmesis of this innovative therapy. Clinical trial information: NCT01162200.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Wang发布了新的文献求助10
1秒前
司徒开山完成签到,获得积分10
2秒前
2秒前
南方姑娘发布了新的文献求助30
2秒前
小米布朗尼完成签到,获得积分10
2秒前
洛尚发布了新的文献求助10
2秒前
syvshc的应助被致行采纳,获得10
3秒前
Lucas的应助被夹心采纳,获得10
3秒前
EIO团队完成签到 ,获得积分10
3秒前
酷波er的应助被肖馨余采纳,获得10
3秒前
3秒前
荼蘼发布了新的文献求助10
4秒前
李桢发布了新的文献求助10
4秒前
4秒前
XUHAO发布了新的文献求助10
4秒前
li完成签到,获得积分10
4秒前
meng发布了新的文献求助30
5秒前
5秒前
柏舟发布了新的文献求助10
5秒前
哈哈哈哈发布了新的文献求助10
5秒前
zz不爱读书完成签到,获得积分10
5秒前
鲤鱼一手完成签到,获得积分10
5秒前
完美世界的应助被Peasein采纳,获得10
5秒前
zhen完成签到,获得积分10
5秒前
领导范儿的应助被聂裕铭采纳,获得10
5秒前
冷艳凌晴完成签到,获得积分20
6秒前
结实机器猫完成签到,获得积分10
6秒前
科研通AI6.4的应助被独特流沙采纳,获得10
6秒前
小蘑菇的应助被HW采纳,获得10
6秒前
6秒前
6秒前
DW的应助被molik采纳,获得10
6秒前
6秒前
123发布了新的文献求助10
6秒前
图图完成签到,获得积分10
6秒前
7秒前
小狮子完成签到,获得积分10
7秒前
共享精神的应助被米米采纳,获得10
7秒前
7秒前
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
Resource Recovery Handbook 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8174559
求助须知:如何正确求助?哪些是违规求助? 9566586
关于积分的说明 21787112
捐赠科研通 7768831
什么是DOI,文献DOI怎么找? 3431746
关于科研通互助平台的介绍 2555956
邀请新用户注册赠送积分活动 2477100